-
公开(公告)号:US20190201448A1
公开(公告)日:2019-07-04
申请号:US16240344
申请日:2019-01-04
申请人: Claude BERNARD
发明人: Claude BERNARD
IPC分类号: A61K35/28 , C12N5/0775 , A61K38/21
CPC分类号: A61K35/28 , A61K35/12 , A61K35/30 , A61K38/215 , A61K2035/122 , A61P25/00 , C12N5/0663 , C12N2506/00 , C12N2506/025 , C12N2506/03 , C12N2506/08 , C12N2506/11 , G01N2333/435 , G01N2333/70503 , G01N2800/24 , G01N2800/28 , A61K2300/00
摘要: The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
-
2.
公开(公告)号:US20180251518A1
公开(公告)日:2018-09-06
申请号:US15971799
申请日:2018-05-04
发明人: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC分类号: C07K14/74 , A61K39/00 , C12N5/0783 , C07K14/47 , G01N33/569 , C12N9/64 , C07K14/00 , G01N33/50 , A61K38/17 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K16/30 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18
CPC分类号: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
3.
公开(公告)号:US20180246114A1
公开(公告)日:2018-08-30
申请号:US15874110
申请日:2018-01-18
发明人: Christian Rohlff
IPC分类号: G01N33/574 , C07K16/28 , A61K39/00 , A61K39/395
CPC分类号: G01N33/57492 , A61K39/39558 , A61K2039/505 , C07K16/2803 , G01N33/57407 , G01N33/57423 , G01N33/57438 , G01N2333/70503
摘要: The present invention provides methods and compositions for screening, diagnosis and prognosis of HCC, glioblastoma and lung cancer, for monitoring the effectiveness of HCC, glioblastoma and lung cancer treatment, and for drug development.
-
公开(公告)号:US10059755B2
公开(公告)日:2018-08-28
申请号:US15789731
申请日:2017-10-20
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: C07K14/70 , C07K14/74 , C12N5/0783 , G01N33/569 , C07K16/28 , A61K45/06 , C07K14/725 , A61K39/00 , C12Q1/6886 , C07K16/30 , C07K14/47 , C07K7/06 , C07K7/02 , A61K38/08 , G01N33/566 , C07K16/18 , C12N9/64
CPC分类号: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号:US20180238905A1
公开(公告)日:2018-08-23
申请号:US15952379
申请日:2018-04-13
IPC分类号: G01N33/68
CPC分类号: G01N33/6893 , C07K14/705 , G01N33/76 , G01N2333/471 , G01N2333/70503 , G01N2560/00 , G01N2800/368 , G01N2800/60
摘要: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.
-
6.
公开(公告)号:US20180238895A1
公开(公告)日:2018-08-23
申请号:US15870449
申请日:2018-01-12
申请人: BioAlliance C.V.
发明人: Rong-Hwa LIN , Leewen LIN , Shih-Yao LIN , Shu-Hua LEE
IPC分类号: G01N33/574 , C07K16/30 , C07K16/28 , A61K39/395 , A61K39/00
CPC分类号: G01N33/57492 , A61K39/39558 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3007 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , G01N2333/70503 , G01N2333/70596
摘要: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
-
公开(公告)号:US20180201680A1
公开(公告)日:2018-07-19
申请号:US15806003
申请日:2017-11-07
IPC分类号: C07K16/28 , A01K67/027 , G01N33/574 , G01N33/68
CPC分类号: C07K16/2803 , A01K67/0278 , A01K2227/105 , A01K2267/01 , C07K16/2827 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , G01N33/57492 , G01N33/6872 , G01N2333/70503 , G01N2800/56
摘要: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
-
公开(公告)号:US09994628B2
公开(公告)日:2018-06-12
申请号:US15638667
申请日:2017-06-30
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: A61K38/00 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/68 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06
CPC分类号: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to the patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
-
9.
公开(公告)号:US20180141993A1
公开(公告)日:2018-05-24
申请号:US15847825
申请日:2017-12-19
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: C07K14/74 , A61K38/17 , C12Q1/6886 , A61K39/00 , A61K45/06 , C12N5/0783 , C12N9/64 , G01N33/50 , G01N33/566 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , C07K16/30 , A61K38/08 , G01N33/569
CPC分类号: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US09932384B2
公开(公告)日:2018-04-03
申请号:US15082933
申请日:2016-03-28
发明人: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号: C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/68 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06
CPC分类号: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-